Gap junction remodeling and spironolactone-dependent reverse remodeling in the hypertrophied heart

Circulation Research

Volumn 104, Issue 3, 2009, Pages 365-371

  Qu, Jiaxiang ^a   Volpicelli, Frank M ^a   Garcia, Luis I ^a   Sandeep, Nefthi ^a   Zhang, Jie ^a   Márquez Rosado, Lucrecia ^b   Lampe, Paul D ^b   Fishman, Glenn I ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Arrhythmias; Connexin; Gap junction; Mouse; Optical mapping; Spironolactone

Indexed keywords

CONNEXIN 43; DYE; SPIRONOLACTONE; DIURETIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ELECTRIC POTENTIAL; GAP JUNCTION; HEART MUSCLE FIBROSIS; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE OVERLOAD; HEART VENTRICLE REMODELING; MALE; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; ANIMAL; C57BL MOUSE; CARDIOMEGALY; CELL JUNCTION; CELL MEMBRANE POTENTIAL; DISEASE MODEL; ECHOGRAPHY; HEART CONTRACTION; HEART MUSCLE CONDUCTION SYSTEM; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY;

ANIMALS; CARDIOMEGALY; CONNEXIN 43; DISEASE MODELS, ANIMAL; DIURETICS; GAP JUNCTIONS; HEART CONDUCTION SYSTEM; MALE; MEMBRANE POTENTIALS; MICE; MICE, INBRED C57BL; MYOCARDIAL CONTRACTION; PHOSPHORYLATION; SPIRONOLACTONE;

EID: 61949425807     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.108.184044     Document Type: Article

References (35)

1. McLenachan JM, Dargie HJ. Left ventricular hypertrophy as a factor in arrhythmias and sudden death. Am J Hypertens. 1989;2:128-131.
2. Kannel WB. Left ventricular hypertrophy as a risk factor: the Framingham experience. J Hypertens Suppl. 1991;9:S3-S8.
3. Messerli FH, Ketelhut R. Left ventricular hypertrophy: an independent risk factor. J Cardiovasc Pharmacol. 1991;17(suppl 4):S59-S66.
4. Messerli FH, Soria F. Hypertension, left ventricular hypertrophy, ventricular ectopy, and sudden death. Am J Med. 1992;93:21S-26S.
5. Haider AW, Larson MG, Benjamin EJ, Levy D. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol. 1998;32:1454-1459.
6. Kang YJ. Cardiac hypertrophy: a risk factor for QT-prolongation and cardiac sudden death. Toxicol Pathol. 2006;34:58-66.
7. Saffitz JE, Kleber AG. Effects of mechanical forces and mediators of hypertrophy on remodeling of gap junctions in the heart. Circ Res. 2004;94:585-591.
8. Teunissen BE, Jongsma HJ, Bierhuizen MF. Regulation of myocardial connexins during hypertrophic remodelling. Eur Heart J. 2004;25: 1979-1989.
9. Dodge SM, Beardslee MA, Darrow BJ, Green KG, Beyer EC, Saffitz JE. Effects of angiotensin II on expression of the gap junction channel protein connexin43 in neonatal rat ventricular myocytes. J Am Coll Cardiol. 1998;32:800-807.
10. Darrow BJ, Fast VG, Kleber AG, Beyer EC, Saffitz JE. Functional and structural assessment of intercellular communication. Increased conduction velocity and enhanced connexin expression in dibutyryl cAMPtreated cultured cardiac myocytes. Circ Res. 1996;79:174-183.
11. Uzzaman M, Honjo H, Takagishi Y, Emdad L, Magee AI, Severs NJ, Kodama I. Remodeling of gap junctional coupling in hypertrophied right ventricles of rats with monocrotaline-induced pulmonary hypertension. Circ Res. 2000;86:871-878.
12. Emdad L, Uzzaman M, Takagishi Y, Honjo H, Uchida T, Severs NJ, Kodama I, Murata Y. Gap junction remodeling in hypertrophied left ventricles of aortic-banded rats: prevention by angiotensin II type 1 receptor blockade. J Mol Cell Cardiol. 2001;33:219-231.
13. Severs NJ, Coppen SR, Dupont E, Yeh HI, Ko YS, Matsushita T. Gap junction alterations in human cardiac disease. Cardiovasc Res. 2004;62: 368-377.
14. Severs NJ, Dupont E, Thomas N, Kaba R, Rothery S, Jain R, Sharpey K, Fry CH. Alterations in cardiac connexin expression in cardiomyopathies. Adv Cardiol. 2006;42:228-242.
15. Formigli L, Ibba-Manneschi L, Perna AM, Pacini A, Polidori L, Nediani C, Modesti PA, Nosi D, Tani A, Celli A, Neri-Serneri GG, Quercioli F, Zecchi-Orlandini S. Altered Cx43 expression during myocardial adaptation to acute and chronic volume overloading. Histol Histopathol. 2003;18:359-369.
16. Rockman HA, Wachhorst SP, Mao L, Ross J Jr. ANG II receptor blockade prevents ventricular hypertrophy and ANF gene expression with pressure overload in mice. Am J Physiol. 1994;266:H2468-H2475.
17. Gutstein DE, Morley GE, Tamaddon H, Vaidya D, Schneider MD, Chen J, Chien KR, Stuhlmann H, Fishman GI. Conduction slowing and sudden arrhythmic death in mice with cardiac-restricted inactivation of connexin43. Circ Res. 2001;88:333-339.
18. Redfern CH, Degtyarev MY, Kwa AT, Salomonis N, Cotte N, Nanevicz T, Fidelman N, Desai K, Vranizan K, Lee EK, Coward P, Shah N, Warrington JA, Fishman GI, Bernstein D, Baker AJ, Conklin BR. Conditional expression of a Gi-coupled receptor causes ventricular conduction delay and a lethal cardiomyopathy. Proc Natl Acad Sci U S A. 2000;97:4826-4831.
19. Gutstein DE, Liu FY, Meyers MB, Choo A, Fishman GI. The organization of adherens junctions and desmosomes at the cardiac intercalated disc is independent of gap junctions. J Cell Sci. 2003;116:875-885.
20. Solan JL, Marquez-Rosado L, Sorgen PL, Thornton PJ, Gafken PR, Lampe PD. Phosphorylation at S365 is a gatekeeper event that changes the structure of Cx43 and prevents down-regulation by PKC. J Cell Biol. 2007;179:1301-1309.
21. Lampe PD, Cooper CD, King TJ, Burt JM. Analysis of connexin43 phosphorylated at S325, S328 and S330 in normoxic and ischemic heart. J Cell Sci. 2006;119:3435-3442.
22. Kalcheva N, Qu J, Sandeep N, Garcia L, Zhang J, Wang Z, Lampe PD, Suadicani SO, Spray DC, Fishman GI. Gap junction remodeling and cardiac arrhythmogenesis in a murine model of oculodentodigital dysplasia. Proc Natl Acad Sci U S A. 2007;104:20512-20516.
23. Leaf DE, Feig JE, Lader JM, Riva PL, Vasquez C, Yu C, Kontogeorgis A, Peters NS, Fisher EA, Gutstein DE, Morley GE. Connexin40 imparts conduction heterogeneity to atrial tissue. Circ Res. 2008;103:1001-1008.
24. Gutstein DE, Morley GE, Fishman GI. Conditional gene targeting of connexin43: exploring the consequences of gap junction remodeling in the heart. Cell Commun Adhes. 2001;8:345-348.
25. Marionneau C, Brunet S, Flagg TP, Pilgram TK, Demolombe S, Nerbonne JM. Distinct cellular and molecular mechanisms underlie functional remodeling of repolarizing K+ currents with left ventricular hypertrophy. Circ Res. 2008;102:1406-1415.
26. Maguire CT, Wakimoto H, Patel VV, Hammer PE, Gauvreau K, Berul CI. Implications of ventricular arrhythmia vulnerability during murine electrophysiology studies. Physiol Genomics. 2003;15:84-91.
27. Ai X, Pogwizd SM. Connexin 43 downregulation and dephosphorylation in nonischemic heart failure is associated with enhanced colocalized protein phosphatase type 2A. Circ Res. 2005;96:54-63.
28. Akar FG, Spragg DD, Tunin RS, Kass DA, Tomaselli GF. Mechanisms underlying conduction slowing and arrhythmogenesis in nonischemic dilated cardiomyopathy. Circ Res. 2004;95:717-725.
29. Poelzing S, Akar FG, Baron E, Rosenbaum DS. Heterogeneous connexin43 expression produces electrophysiological heterogeneities across ventricular wall. Am J Physiol. 2004;286:H2001-H2009.
30. Akar FG, Nass RD, Hahn S, Cingolani E, Shah M, Hesketh GG, DiSilvestre D, Tunin RS, Kass DA, Tomaselli GF. Dynamic changes in conduction velocity and gap junction properties during development of pacing-induced heart failure. Am J Physiol. 2007;293:H1223-H1230.
31. Cooper CD, Lampe PD. Casein kinase 1 regulates connexin-43 gap junction assembly. J Biol Chem. 2002;277:44962-44968.
32. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-717.
33. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321.
34. Kuster GM, Kotlyar E, Rude MK, Siwik DA, Liao R, Colucci WS, Sam F. Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload. Circulation. 2005;111:420-427.
35. Boixel C, Gavillet B, Rougier JS, Abriel H. Aldosterone increases voltage-gated sodium current in ventricular myocytes. Am J Physiol. 2006;290:H2257-H2266.